Point72 Asset Management L.P. Makes New $3.81 Million Investment in Capricor Therapeutics Inc (NASDAQ:CAPR)

Point72 Asset Management L.P. bought a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 250,204 shares of the biotechnology company’s stock, valued at approximately $3,806,000.

Several other hedge funds and other institutional investors have also modified their holdings of CAPR. Main Street Financial Solutions LLC raised its position in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 7,500 shares during the period. SG Americas Securities LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $133,000. Rhumbline Advisers acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at about $147,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics in the third quarter worth approximately $161,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Capricor Therapeutics by 868.7% during the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 15,872 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Insider Transactions at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.00% of the stock is currently owned by corporate insiders.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $14.86 on Monday. Capricor Therapeutics Inc has a one year low of $3.24 and a one year high of $23.40. The company’s fifty day moving average price is $18.69 and its two-hundred day moving average price is $9.78. The company has a market capitalization of $675.68 million, a price-to-earnings ratio of -14.02 and a beta of 3.98.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CAPR shares. Maxim Group upped their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Piper Sandler began coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald raised their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.